<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429767</article-id><article-id pub-id-type="pmcid-ver">PMC12429767.1</article-id><article-id pub-id-type="pmcaid">12429767</article-id><article-id pub-id-type="pmcaiid">12429767</article-id><article-id pub-id-type="doi">10.3390/ijms26178526</article-id><article-id pub-id-type="publisher-id">ijms-26-08526</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-3365-8556</contrib-id><name name-style="western"><surname>Vuleta Nedic</surname><given-names initials="K">Katarina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijms-26-08526" ref-type="aff">1</xref><xref rid="af2-ijms-26-08526" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0535-2964</contrib-id><name name-style="western"><surname>Gajovic</surname><given-names initials="N">Nevena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af3-ijms-26-08526" ref-type="aff">3</xref><xref rid="c1-ijms-26-08526" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1169-2378</contrib-id><name name-style="western"><surname>Jovanovic</surname><given-names initials="I">Ivan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-ijms-26-08526" ref-type="aff">3</xref><xref rid="af4-ijms-26-08526" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jurisevic</surname><given-names initials="M">Milena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af3-ijms-26-08526" ref-type="aff">3</xref><xref rid="af5-ijms-26-08526" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2441-7914</contrib-id><name name-style="western"><surname>Jovanovic</surname><given-names initials="M">Marina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af3-ijms-26-08526" ref-type="aff">3</xref><xref rid="af6-ijms-26-08526" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jakovljevi&#263;</surname><given-names initials="S">Slobodan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af3-ijms-26-08526" ref-type="aff">3</xref><xref rid="af7-ijms-26-08526" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Popovic</surname><given-names initials="B">Bojana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af8-ijms-26-08526" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-1538-4390</contrib-id><name name-style="western"><surname>Djordjevic</surname><given-names initials="J">Jelena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-ijms-26-08526" ref-type="aff">1</xref><xref rid="af2-ijms-26-08526" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3045-4754</contrib-id><name name-style="western"><surname>Ignjatovic</surname><given-names initials="V">Vesna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-ijms-26-08526" ref-type="aff">1</xref><xref rid="af2-ijms-26-08526" ref-type="aff">2</xref><xref rid="c1-ijms-26-08526" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7886-885X</contrib-id><name name-style="western"><surname>Vukomanovic</surname><given-names initials="V">Vladimir</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-ijms-26-08526" ref-type="aff">1</xref><xref rid="af2-ijms-26-08526" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Treglia</surname><given-names initials="G">Giorgio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-26-08526"><label>1</label>Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia; <email>kvuleta87@gmail.com</email> (K.V.N.); <email>jeladj997@gmail.com</email> (J.D.); <email>vukomanovic@gmail.com</email> (V.V.)</aff><aff id="af2-ijms-26-08526"><label>2</label>Department for Nuclear Medicine, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia</aff><aff id="af3-ijms-26-08526"><label>3</label>Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia; <email>ivanjovanovic77@gmail.com</email> (I.J.); <email>milena.jurisevic13@gmail.com</email> (M.J.); <email>marina_jovanovic@rocketmail.com</email> (M.J.); <email>jakovljevicslobodan@gmail.com</email> (S.J.)</aff><aff id="af4-ijms-26-08526"><label>4</label>Faculty of Medicine, University of East Sarajevo, 73300 Foca, Bosnia and Herzegovina</aff><aff id="af5-ijms-26-08526"><label>5</label>Department of Clinical Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia</aff><aff id="af6-ijms-26-08526"><label>6</label>Department of Otorhinolaryngology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia</aff><aff id="af7-ijms-26-08526"><label>7</label>Department of Surgery, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia</aff><aff id="af8-ijms-26-08526"><label>8</label>Clinic of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, 11000 Beograd, Serbia; <email>popbojana@gmail.com</email></aff><author-notes><corresp id="c1-ijms-26-08526"><label>*</label>Correspondence: <email>gajovicnevena@yahoo.com</email> (N.G.); <email>vesnaivladaignjatovic@gmail.com</email> (V.I.)</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>26</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496188</issue-id><elocation-id>8526</elocation-id><history><date date-type="received"><day>02</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-08526.pdf"/><abstract><p>Despite a high disease control rate in the treatment of unresectable or metastatic well-differentiated, somatostatin receptor-positive neuroendocrine tumors (NETs) with peptide receptor radionuclide therapy (PRRT), a certain percentage of patients will experience an unfavorable outcome. Besides clinical, hematological, and biochemical parameters, including widely used inflammatory markers, as well as literature-recognized inflammatory indices, there is a growing need for the identification of novel biomarkers as prognostic factors of therapeutic response. In this prospective single-center study, 51 NET patients treated with PRRT were included and divided into two groups: responders and non-responders in accordance with therapeutic outcome. Cytokine, clinical, and biochemical data were analyzed. Non-responders had significantly higher serum concentrations of IL-33 and IL-4 in comparison to responders, while sST2 was increased in responders. A positive correlation was measured between IL-33 and IL-4, as well as between IL-33 and disease progression. A negative correlation was noted between IL-33 and the neutrophil count %. ROC curve analysis identified values of IL-33 &gt;146.5 pg/mL as a predictor of poor early therapeutic response, and logistic regression confirmed its independent prognostic value. Elevated IL-33 and IL-4 favor the development of a type 2 immune response associated with unfavored therapeutic outcome, while increased sST2 mitigates the IL-33&#8217;s effect in responders, contributing to a more favorable response. These findings emphasize IL-33 as an important biomarker of early response in NET patients undergoing PRRT.</p></abstract><kwd-group><kwd>neuroendocrine tumors</kwd><kwd>peptide receptor radionuclide therapy</kwd><kwd>IL-33</kwd><kwd>sST2</kwd></kwd-group><funding-group><award-group><funding-source>University of Kragujevac, Faculty of Medical Sciences</funding-source><award-id>12/24</award-id></award-group><funding-statement>This study was supported by the University of Kragujevac, Faculty of Medical Sciences (Junior Project N&#176; 12/24).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-26-08526"><title>1. Introduction</title><p>Neuroendocrine tumors (NETs) are a rare, biologically and clinically heterogeneous group of neoplasms characterized by their capacity for the synthesis, storage, and secretion of various neuroamines and peptides, occasionally resulting in secretory syndromes. However, the majority of neuroendocrine neoplasms are nonfunctional and can remain clinically silent for extensive periods, delaying the diagnosis. Predominantly arising from the gastrointestinal and bronchopulmonary systems, these tumors have shown an increase in incidence over the past three decades [<xref rid="B1-ijms-26-08526" ref-type="bibr">1</xref>,<xref rid="B2-ijms-26-08526" ref-type="bibr">2</xref>]. Peptide receptor radionuclide therapy (PRRT) has been established as an effective treatment option for unresectable or metastatic neuroendocrine tumors (NETs) in the last twenty years. By targeting tumor cells through binding to widely expressed somatostatin receptors (SSTRs), PRRT enables selective radiopharmaceutical delivery and radiation-induced cell death. Reliable randomized clinical trials demonstrated its favorable safety profile while achieving disease control in most cases [<xref rid="B3-ijms-26-08526" ref-type="bibr">3</xref>]. Nevertheless, a considerable number of NET patients undergoing PRRT will experience disease progression [<xref rid="B4-ijms-26-08526" ref-type="bibr">4</xref>].</p><p>Numerous studies have focused on identifying factors predicting disease progression and treatment outcomes during PRRT. These factors primarily include specific clinical parameters, blood-based biomarkers, and morphological or functional imaging [<xref rid="B5-ijms-26-08526" ref-type="bibr">5</xref>].</p><p>Since immune mediators affect not only tumor cell proliferation, survival, angiogenesis, and metastasis, but also the response to the various therapeutic modalities, several studies have investigated the role of inflammatory markers as predictive factors in patients with NETs treated with PRRT [<xref rid="B6-ijms-26-08526" ref-type="bibr">6</xref>,<xref rid="B7-ijms-26-08526" ref-type="bibr">7</xref>,<xref rid="B8-ijms-26-08526" ref-type="bibr">8</xref>]. While limited studies have pointed out the predictive impact of a small subset of inflammatory markers, such as C-reactive protein (CRP), composite index as Platelet &#215; CRP multiplier (PCM), CPR/albumin ratio, absolute neutrophil count, and platelet-to-lymphocyte ratio (PLR), further research is required to improve and identify novel inflammatory biomarkers, including cytokines [<xref rid="B7-ijms-26-08526" ref-type="bibr">7</xref>,<xref rid="B9-ijms-26-08526" ref-type="bibr">9</xref>]. Cytokine profiling may offer valuable insights into the biological response during PRRT and help identify specific cytokines as potential biomarkers of PRRT efficacy.</p><p>IL-33 is a cytokine that may play a dual role as a pro- or anti-tumorigenic mediator. Increased IL-33 in serum or tumor tissue may correlate with poor prognosis in several types of cancers, while, on the contrary, IL-33 can also stimulate anti-tumor immune response and thus contributes to tumor cell elimination [<xref rid="B10-ijms-26-08526" ref-type="bibr">10</xref>]. In contrast, its soluble receptor sST2 acts like a decoy receptor, with an attenuating effect on IL-33 signaling [<xref rid="B11-ijms-26-08526" ref-type="bibr">11</xref>]. Recent studies point to the role of the IL-33/sST2 axis as a valuable immunoinflammatory biomarker in cancer [<xref rid="B12-ijms-26-08526" ref-type="bibr">12</xref>]. Alongside this axis, some studies suggest the complex interaction between IL-33 and IL-4 that has a well-established regulatory role in the cancer microenvironment associated with cell survival, proliferation, and metastasis [<xref rid="B13-ijms-26-08526" ref-type="bibr">13</xref>,<xref rid="B14-ijms-26-08526" ref-type="bibr">14</xref>].</p><p>The main aim of this study was to analyze the relationship between clinical, hematological, and standard biochemical parameters, as well as cytokine profile and PRRT outcome.</p></sec><sec sec-type="results" id="sec2-ijms-26-08526"><title>2. Results</title><sec sec-type="subjects" id="sec2dot1-ijms-26-08526"><title>2.1. Demographic and Clinical Features of NET Patients</title><p>A total of 51 patients were enrolled in this study, with a mean age at the time of treatment of 58 &#177; 1.7 years (range: 30&#8211;83 years). Of these, 22 patients (43.1%) were male and 29 patients (56.9%) were female. All patients had a good performance status&#8212;ECOG 0&#8211;1. The most common primary sites of NETs were Gastroenteropancreatic (GEP-NETs), present in 37 patients (72.5%), followed by unknown primary NETs in 7 patients (13.7%), lung-NETs in 4 patients (7.9%), and others (5.9%). According to interim multidetector computed tomography (<italic toggle="yes">MDCT</italic>) or magnetic resonance imaging (<italic toggle="yes">MRI</italic>), disease control was achieved in 8 patients (15.7%) with partial response (PR) and 29 patients (56.9%) with stable disease (SD). Disease progression was observed (PD) in 14 patients (27.4%). Patients with PR and SD are classified as responders (72.6%), whereas those with PD were considered non-responders (27.4%). PRRT was administered in combination with long-acting somatostatin analogs (SSAs) in all patients except one. Other patient characteristics are detailed in <xref rid="ijms-26-08526-t001" ref-type="table">Table 1</xref>.</p></sec><sec sec-type="subjects" id="sec2dot2-ijms-26-08526"><title>2.2. Laboratory Analyses of NET Patients</title><p>Significant differences in laboratory parameters were found between the group of responders and non-responders. In the non-responder group, the decrease in white blood cell count (<italic toggle="yes">p</italic> = 0.013, <italic toggle="yes">p</italic> = 0.04), neutrophil count (<italic toggle="yes">p</italic> = 0.037, <italic toggle="yes">p</italic> = 0.039), lymphocyte count (<italic toggle="yes">p</italic> = 0.03, <italic toggle="yes">p</italic> = 0.03), monocyte count (<italic toggle="yes">p</italic> = 0.002, <italic toggle="yes">p</italic> = 0.029), platelets (<italic toggle="yes">p</italic> = 0.021, <italic toggle="yes">p</italic> = 0.014), SIRI (<italic toggle="yes">p</italic> = 0.021, <italic toggle="yes">p</italic> = 0.049), SII (<italic toggle="yes">p</italic> = 0.026, <italic toggle="yes">p</italic> = 0.049) and vitamin D (<italic toggle="yes">p</italic> = 0.037, <italic toggle="yes">p</italic> = 0.029) were noted both before initiation of PRRT and prior to the second cycle, compared to the responder group. Additionally, significantly higher values of AST (<italic toggle="yes">p</italic> = 0.039), ALT (<italic toggle="yes">p</italic> = 0.029), CgA (<italic toggle="yes">p</italic> = 0.036), and 5-HIAA (<italic toggle="yes">p</italic> = 0.03) were measured in non-responders than in responders at the second time point. There were no statistically significant differences in other laboratory parameters between the two groups (<xref rid="ijms-26-08526-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot3-ijms-26-08526"><title>2.3. NET Patients with Disease Progression Had Elevated Systemic Level of IL-33</title><p>Serum levels of pro- and anti-inflammatory cytokines were measured in patients with stable and progressive disease. Systemic values of IL-33 (<italic toggle="yes">p</italic> = 0.001) and IL-4 (<italic toggle="yes">p</italic> = 0.001) were significantly lower in responders in comparison to patients with a more severe form of disease, while soluble ST2 (<italic toggle="yes">p</italic> = 0.001) was significantly higher in responders (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>A&#8211;C). Although serum level of TNF-&#945; was higher in responders, this alteration did not reach statistical significance (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>D). However, for the purpose of insight into the relationship between counterregulatory cytokines, analyses of ratios of TNF-&#945; with IL-33 and IL-4 were performed. Results revealed that TNF-&#945;/IL-33 (<italic toggle="yes">p</italic> = 0.001) as well as TNF-&#945;/IL-4 (<italic toggle="yes">p</italic> = 0.001) ratios were significantly increased in responders in comparison to non-responders (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>E,F).</p></sec><sec id="sec2dot4-ijms-26-08526"><title>2.4. IL-33 Correlates with the Disease Progression</title><p>As IL-33, together with sST2, were the most prominent among other measured cytokines, we further correlated these two mediators with other cytokines and clinical and laboratory parameters. Strong positive correlation was detected between IL-33 and IL-4 (<italic toggle="yes">p</italic> = 0.001). Moreover, IL-33 positively correlated with disease progression (<italic toggle="yes">p</italic> = 0.037), while a negative correlation was measured with neutrophil count % (<italic toggle="yes">p</italic> = 0.041) (<xref rid="ijms-26-08526-t003" ref-type="table">Table 3</xref>). sSt2 showed positive correlation with absolute neutrophil count (<italic toggle="yes">p</italic> = 0.022) and gamma glutamyl transferase (<italic toggle="yes">p</italic> = 0.033), while negative correlation was noted between sST2 and triglyceride (<italic toggle="yes">p</italic> = 0.049) and lipase (<italic toggle="yes">p</italic> = 0.001), respectively (<xref rid="ijms-26-08526-t003" ref-type="table">Table 3</xref>). The ROC curve analysis of IL-33 to differentiate better responders and worse responders to therapy detected that the optimum cut-off point for IL-33 was 146.5 pg/mL (AUC 0.689; 95%CI 0.525&#8211;0.853; Sensitivity 64.3%; Specificity 70.3%; <italic toggle="yes">p</italic> = 0.039).</p><p>The univariate logistic regression analysis showed that Ki67(&gt;10%) (OR 4.255, 95% CI 1.159&#8211;15.625; <italic toggle="yes">p</italic> = 0.029) and IL-33 (&gt;147 pg/mL) (OR 4.552, 95% CI 11.159&#8211;15.628; <italic toggle="yes">p</italic> = 0.029) were significant risk factors for disease progression (<xref rid="ijms-26-08526-t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-26-08526"><title>3. Discussion</title><p>The aim of this study was to assess the association between clinical characteristics, laboratory parameters, and immune cytokine profile with PRRT outcome. NET patients were divided into two groups (responders and non-responders) according to the criteria described in the Materials and Methods section.</p><p>Concerning clinical parameters, no significant differences were observed between responders and non-responders (<xref rid="ijms-26-08526-t001" ref-type="table">Table 1</xref>). While some reports suggest that younger patients have a better response to PRRT [<xref rid="B15-ijms-26-08526" ref-type="bibr">15</xref>], others did not reveal significant differences in outcome regarding age and gender, supporting our findings [<xref rid="B16-ijms-26-08526" ref-type="bibr">16</xref>,<xref rid="B17-ijms-26-08526" ref-type="bibr">17</xref>]. The prognostic significance of primary tumor location in neuroendocrine neoplasms has been well established in epidemiological research [<xref rid="B1-ijms-26-08526" ref-type="bibr">1</xref>]. Consistent with the previous study [<xref rid="B18-ijms-26-08526" ref-type="bibr">18</xref>], our analysis also demonstrated that GEP-NETs were predominantly represented among both responders and non-responders compared to lung-NETs, unknown primary NETs, and other primary sites, although this did not reach statistical significance. Nevertheless, further studies with larger cohorts are needed to fully assess the efficacy of PRRT in non-GEP-NETs in comparison to GEP-NETs.</p><p>In addition, our study revealed significantly lower baseline and intratherapeutic values of white blood cells, neutrophils, lymphocytes, monocytes, platelets, SIRI, SII, and vitamin D in the non-responder group.</p><p>Some previous studies have shown that tumor progression is promoted by chronic inflammation, resulting in poorer PRRT outcomes. Increased levels of inflammatory markers such as neutrophils, CRP, CRP/Alb, and composite indices like NLR, PLR, SIRI, and SII have been associated with more aggressive tumor behavior, immunosuppressive tumor microenvironment, and limited therapeutic efficacy [<xref rid="B7-ijms-26-08526" ref-type="bibr">7</xref>,<xref rid="B8-ijms-26-08526" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-08526" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-08526" ref-type="bibr">10</xref>,<xref rid="B19-ijms-26-08526" ref-type="bibr">19</xref>]. Contrarily, this study found that a decreased number of neutrophils, lymphocytes, monocytes, and platelet counts may imply that the immune system is potentially compromised or myelosuppressed, leading to ineffective anti-tumor responses and PRRT&#8217;s reduced efficacy. Vitamin D levels were also significantly reduced in non-responders before the start of PRRT and before the second cycle. Interestingly, recent work of Modica et al. demonstrated that patients with lung NETs and bone metastases had vitamin D insufficiency, with significantly lower vitamin D levels compared to patients with lung NETs without bone metastases, suggesting a possible role of hypovitaminosis D in bone metastasis development and, thereby, disease progression [<xref rid="B20-ijms-26-08526" ref-type="bibr">20</xref>]. These findings support previously published data about the role of vitamin D as an immunomodulator in the context of tumor immunity [<xref rid="B21-ijms-26-08526" ref-type="bibr">21</xref>].</p><p>The enzymes AST and ALT are standard parameters in the assessment of liver function. While ALT is specific for hepatocytes, AST is expressed in other tissues, such as skeletal muscle, cardiac muscle, and kidney [<xref rid="B22-ijms-26-08526" ref-type="bibr">22</xref>]. Therefore, elevated AST values without a concomitant increase in ALT may imply extrahepatic pathology rather than primary liver damage [<xref rid="B23-ijms-26-08526" ref-type="bibr">23</xref>]. However, increased AST levels in non-responders undergoing PRRT, as demonstrated in our study, may indicate an altered tumor cell metabolism, specifically, anaerobic glycolysis, known in the literature as the &#8220;Warburg effect&#8221; [<xref rid="B24-ijms-26-08526" ref-type="bibr">24</xref>]. This metabolic adaptation modulates the activity of AST, since AST is needed for the maintenance of high proliferation rates of cancer cells [<xref rid="B25-ijms-26-08526" ref-type="bibr">25</xref>].</p><p>Higher ALP levels are associated with worse outcomes in several cancers and may act as a prognostic marker, particularly in patients with liver or bone metastatic disease [<xref rid="B26-ijms-26-08526" ref-type="bibr">26</xref>,<xref rid="B27-ijms-26-08526" ref-type="bibr">27</xref>]. Moreover, a recent prospective study indicates that ALP may serve as a strong prognostic marker in patients with advanced digestive NET G3 and neuroendocrine carcinomas (NEC), which is consistent with our findings [<xref rid="B28-ijms-26-08526" ref-type="bibr">28</xref>].</p><p>Chromogranin A (CgA) has been used as a valuable tumor marker in NETs, and elevated levels of both CgA and 5-hydroxyindoleacetic acid (5-HIAA) have previously been associated with poor prognosis in these patients [<xref rid="B18-ijms-26-08526" ref-type="bibr">18</xref>,<xref rid="B29-ijms-26-08526" ref-type="bibr">29</xref>]. Comparable results, especially regarding the monitoring of these markers throughout treatment, have also been documented in our research.</p><p>The immune system plays an important role in the development and progression of neuroendocrine tumors (NETs) [<xref rid="B30-ijms-26-08526" ref-type="bibr">30</xref>]. Although the first synonym for NETs was immunologically &#8220;cold&#8221; tumors because of the reduced expression of tumor antigens and lack of stimulation of immune response, in recent years, multiple data points on the importance of immune-mediated mechanisms in the pathogenesis and outcome of patients with NET [<xref rid="B31-ijms-26-08526" ref-type="bibr">31</xref>]. Previous investigations revealed a non-negligible role of pro- and anti-inflammatory cytokines in different biological processes of neuroendocrine tumors [<xref rid="B32-ijms-26-08526" ref-type="bibr">32</xref>]. As cytokines can also affect and modulate the effectiveness of therapy, we investigated serum cytokine profiles in NET responders and non-responders. Our results demonstrate a significant increment in serum concentrations of IL-33 and IL-4 in non-responders in comparison to responders, while, on the contrary, sST2 was significantly higher in responders (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>). Previous studies have also described an obvious correlation between IL-33 levels and tumor prognosis. Ishikawa et al. showed that IL-33 expression was significantly elevated in patients with a more severe form of squamous cell carcinoma of the tongue, pointing to the important contribution of the IL-33/ST2 axis to tumor progression [<xref rid="B33-ijms-26-08526" ref-type="bibr">33</xref>].</p><p>IL-33 is a member of the IL-1 family of cytokines that can be involved in different pathways in immune response and tumor biology [<xref rid="B34-ijms-26-08526" ref-type="bibr">34</xref>]. Released from destroyed and necrotic cells, IL-33 acts as an alarmin, stimulating different immune and non-immune cells [<xref rid="B35-ijms-26-08526" ref-type="bibr">35</xref>]. The possible explanation for the increment of IL-33 may be that non-responders have an increased amount of destroyed cells able to release IL-33 that further activates innate lymphoid cells type 2 and Th2 cells as members of the type 2 immune response [<xref rid="B36-ijms-26-08526" ref-type="bibr">36</xref>,<xref rid="B37-ijms-26-08526" ref-type="bibr">37</xref>]. Increased levels of IL-33 and IL-4 suggested the predominance of type 2 immune response in non-responder NET patients, which may contribute to the worse therapeutic outcome and favor immune suppression [<xref rid="B38-ijms-26-08526" ref-type="bibr">38</xref>]. Moreover, a strong positive correlation was detected between IL-33 and IL-4 in our study (<xref rid="ijms-26-08526-t003" ref-type="table">Table 3</xref>). These results, together with previous findings, can support the hypothesis that by favoring type 2 immunity, increased IL-33 and IL-4 promote an immunosuppressive state followed by tumor progression [<xref rid="B39-ijms-26-08526" ref-type="bibr">39</xref>]. On the other hand, TNF-&#945;/IL-33, as well as TNF-&#945;/IL-4 ratios, were significantly increased in responders compared to non-responders (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>). While TNF-&#945; is a proinflammatory cytokine, crucial for promoting a strong and functional type 1 anti-tumor immune response, IL-33 and IL-4 are associated with immunosuppression and tumor promotion [<xref rid="B40-ijms-26-08526" ref-type="bibr">40</xref>,<xref rid="B41-ijms-26-08526" ref-type="bibr">41</xref>,<xref rid="B42-ijms-26-08526" ref-type="bibr">42</xref>]. Higher TNF-&#945;/IL-33 and TNF-&#945;/IL-4 ratios in responders suggest the predominance of proinflammatory potent stimulator TNF-&#945; of anti-tumor immune response in NET patients who responded better to therapy and diminished immunosuppressive effect of IL-33 and IL-4. The importance of IL-33 in NET patients is supported by a positive correlation that is detected between IL-33 and disease progression (<xref rid="ijms-26-08526-t003" ref-type="table">Table 3</xref>). Several studies have shown that expression of IL-33 correlates with tumor aggressiveness and poor prognosis of cancer patients [<xref rid="B30-ijms-26-08526" ref-type="bibr">30</xref>,<xref rid="B43-ijms-26-08526" ref-type="bibr">43</xref>]. It is possible that increased release of IL-33 contributes to less potent type 2 anti-tumor immunity and diminishes functional anti-tumor immune response. This continuous immune dysregulation may facilitate tumor progression and be associated with poor therapeutic outcomes. Moreover, a negative correlation was detected between IL-33 and neutrophil count point, indicating that elevated IL-33 may suppress neutrophil-mediated anti-tumor immune response (<xref rid="ijms-26-08526-t003" ref-type="table">Table 3</xref>). As neutrophils are involved in the early response to tumors, this suppression can facilitate immune evasion and consequently worsen therapeutic response [<xref rid="B44-ijms-26-08526" ref-type="bibr">44</xref>]. The effect of IL-33 can be neutralized in the case of the presence of the soluble ST2 (sST2) molecule, which serves as a decoy receptor for this cytokine [<xref rid="B45-ijms-26-08526" ref-type="bibr">45</xref>]. Our results showed that systemic sST2 is significantly increased in responders in comparison to non-responders (<xref rid="ijms-26-08526-f001" ref-type="fig">Figure 1</xref>). The fact that increased sST2 dominates in responders, together with decreased levels of IL-33, may suggest a potential protective role of sST2 in neutralizing the pro-tumorigenic and immunosuppressive effect of IL-33, thus contributing to a better therapeutic response [<xref rid="B46-ijms-26-08526" ref-type="bibr">46</xref>].</p><p>Importantly, we calculated a clinically relevant cut-off value for IL-33 of 146.5 pg/mL as a potential prognostic marker for therapeutic response in patients with neuroendocrine tumors. Patients with systemic levels of IL-33 above this critical value developed significantly poorer therapeutic response in comparison to patients with IL-33 levels below 146.5 pg/mL. This finding points to a possible association of increased IL-33 with a more progressive tumor phenotype or disease progression. Measuring IL-33 prior to PRRT may be helpful in stratifying patients and predicting therapeutic outcome.</p></sec><sec id="sec4-ijms-26-08526"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-26-08526"><title>4.1. Patient Population</title><p>This prospective, cross-sectional, single-center study included 51 patients with well-differentiated neuroendocrine tumors undergoing PRRT, which was conducted during the years 2022&#8211;2025 at the University Clinical Center Kragujevac, Serbia. All patients receiving PRRT were previously assessed, and the treatment decision was made by the NETs&#8217; dedicated multidisciplinary tumor board. Study&#8217;s inclusion criteria, including being over 18 years of age, having a pathologically confirmed diagnosis of a neuroendocrine tumor, and demonstrating somatostatin receptor expression on diagnostic scintigraphy with 99mTc-HYNIC-TOC (Tektrotyd&#174;, IAE POLATOM, Otwock, Poland) were met by all participants. Patients with bone marrow suppression, impaired renal function, or concurrent malignancies were omitted from this study. None of the enrolled patients were treated with antibiotics, amino salicylates, corticosteroids, statins, immunosuppressive agents, or any kind of biological therapy for at least 2 months before the beginning of this study.</p><p>The research was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Clinical Center Kragujevac (No. 01/22-385). Written informed consent was obtained from all participants.</p></sec><sec id="sec4dot2-ijms-26-08526"><title>4.2. Data Collection</title><p>Data were collected from patients&#8217; medical records and summarized in patient demographics (age, gender) and clinicopathological characteristics, including performance status (Eastern Cooperative Oncology Group (ECOG)), primary tumor location, metastatic dissemination in lymph nodes, liver, and bones, tumor grade, Ki-67 index, and tumor functionality. Tumor functionality was defined by presence of carcinoid syndrome, the most frequent functional manifestation of NETs and determined as presence of clinical symptoms related to carcinoid heart disease, diarrhea, flushing, and abdominal pain, or by elevated levels of biochemical markers such as, 24-h urine 5-hydroxyindoleacetic acid (5-HIAA), while chromogranin A (CgA) and neuron-specific enolase (<italic toggle="yes">NSE</italic>) were determined as general biomarkers [<xref rid="B2-ijms-26-08526" ref-type="bibr">2</xref>,<xref rid="B47-ijms-26-08526" ref-type="bibr">47</xref>].</p></sec><sec id="sec4dot3-ijms-26-08526"><title>4.3. Sampling</title><p>Patients&#8217; blood was sampled on the day of admission at the Department for Nuclear Medicine, prior to the initial and before each subsequent cycle of PRRT. Complete blood count and selected biochemical analyses were performed at the Laboratory Diagnostic Service of the University Clinical Center Kragujevac. Serum cytokine levels were assessed at the Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac.</p></sec><sec id="sec4dot4-ijms-26-08526"><title>4.4. Evaluation</title><sec id="sec4dot4dot1-ijms-26-08526"><title>4.4.1. Determination of Hematological, Standard Biochemical Parameters, and Hematological/Biochemical Indices</title><p>Hematological parameters, including white blood count (WBC) and its subpopulations (neutrophils, lymphocytes, monocytes), red blood cells (RBC), hemoglobin (HGB), and platelets (PLT), were analyzed using the DxH 800 hematology analyzer.</p><p>Biochemical parameters, such as urea, creatinine, total proteins, albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and vitamin D, were measured with the Beckman Coulter AU5800 analyzer by spectrophotometric method. C-reactive protein (CRP) concentration was determined using the turbidimetric method with CRP Latex Beckman Coulter reagents on the same analyzer. While plasma chromogranin A and Urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were determined using appropriate ELISA kits, neuron-specific enolase (NSE) was measured by an immunoradiometric assay (IRMA).</p><p>Additionally, specific hematological and biochemical indices identified as prognostic markers in cancer patients were calculated. These include the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI: neutrophils &#215; monocytes/lymphocytes), systemic immune-inflammation index (SII: neutrophils &#215; platelets/lymphocytes), CRP-to-albumin ratio (CRP/Alb), HALP score (hemoglobin &#215; albumin &#215; lymphocytes/platelets), and the De Ritis ratio (AST/ALT) [<xref rid="B19-ijms-26-08526" ref-type="bibr">19</xref>,<xref rid="B48-ijms-26-08526" ref-type="bibr">48</xref>,<xref rid="B49-ijms-26-08526" ref-type="bibr">49</xref>,<xref rid="B50-ijms-26-08526" ref-type="bibr">50</xref>].</p></sec><sec id="sec4dot4dot2-ijms-26-08526"><title>4.4.2. Measurement of TNF-&#945;, IL-4, IL-6, IL-10, IL-17, IL-33, IL-41, sST2, Galectin-1 and Galectin-3 in Sera</title><p>The concentrations of TNF-&#945;, IL-4, IL-6, IL-10, IL-17, IL-33, IL-41, sST2, Gal-1, and Gal-3 were quantified from serum samples taken prior to the 1st PRRT cycle using commercial ELISA kits specific to human cytokines (R&amp;D Systems, Minneapolis, MN, USA) [<xref rid="B51-ijms-26-08526" ref-type="bibr">51</xref>].</p></sec></sec><sec id="sec4dot5-ijms-26-08526"><title>4.5. PRRT and Response</title><p>All patients received at least two PRRT cycles in accordance with a standardized protocol with [177Lu]Lu-DOTATOC at a dosage of 5.5 GBq per cycle. The time interval between cycles was 8&#8211;12 weeks, consisting of a median of three treatment cycles (varying between 2 and 6 cycles). The interim staging was performed 6&#8211;8 weeks after two PRRT cycles using contrast-enhanced MDCT (Siemens SOMATOM go.Top, Siemens Healthineers, Erlangen, Germany) or MRI (Siemens Magnetom Avanto 1.5 T, Siemens Healthineers, Erlangen, Germany), depending on the initial imaging modality that was used at the time of diagnosis, as well as throughout the follow-up. All MDCT and MRI imaging examinations were conducted at the University Clinical Center Kragujevac and interpreted by experienced radiologists. Interim imaging findings were compared with those obtained before initiation of PRRT. According to the RECIST 1.1 criteria, patients were classified into two groups: responders, including stable disease (SD) and partial response (PR), and non-responders with progressive disease (PD). Patients with confirmed disease progression discontinued PRRT, given the decision of the NETs dedicated multidisciplinary tumor board [<xref rid="B52-ijms-26-08526" ref-type="bibr">52</xref>].</p></sec><sec id="sec4dot6-ijms-26-08526"><title>4.6. Statistical Analysis</title><p>Statistical analyses were conducted using SPSS software for Windows (version 20.0). Continuous variables were expressed as mean &#177; standard error of measurement (SEM), while categorical variables were presented as proportions/percentages. To assess the normality of data distribution Kolmogorov&#8211;Smirnov and Shapiro&#8211;Wilk tests were employed. Based on the distribution characteristics, either parametric or nonparametric tests were applied (Student&#8217;s <italic toggle="yes">t</italic>-test or Mann&#8211;Whitney U test). For categorical data, the Chi-squared test was performed. Linear correlation analyses were performed using Pearson&#8217;s correlation coefficient for normally distributed data and Spearman&#8217;s rank correlation coefficient for non-normally distributed data. To evaluate the relationship between sensitivity and specificity, as well as the discriminative ability of a variable as a potential biomarker, Receiver Operating Characteristic (ROC) curve analysis was conducted. All statistical tests were performed at a 95% confidence level (CI), with <italic toggle="yes">p</italic>-values &#8804; 0.05 considered statistically significant. Strength of correlation was defined as negative or positive weak (&#8722;0.3 to&#8201;&#8722;0.1 or 0.1 to 0.3), moderate (&#8722;0.5 to &#8722;0.3 or 0.3 to 0.5), or strong (&#8722;1.0 to &#8722;0.5 or 0.5 to 1.0). Univariate binary logistic regression was performed to investigate the association of independent variables (initial laboratory results) with unfavorable therapeutic outcomes.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-26-08526"><title>5. Conclusions</title><p>Taken together, the results of our study suggest that increased levels of IL-33 and IL-4 are responsible for the development of a less favorable type 2 anti-tumor immune response, which contributes to worse therapeutic response. An additional confirmation of IL-33 as a marker of poor early response in NET patients undergoing PRRT is the result that an elevated level of sST2 serves as a compensatory mechanism in responders, giving a possibility for a better therapeutic response. Our results suggest that pre-treatment measurement of IL-33 may serve as a useful biomarker for predicting poor early therapeutic outcomes in patients with neuroendocrine tumors.</p></sec><sec id="sec6-ijms-26-08526"><title>6. Limitations</title><p>Limitations of this study are a relatively small sample size and population heterogeneity. These limitations are expected and consistent with other studies in this area, considering the low incidence of NETs and the limited number of patients eligible for PRRT. Although our study was the first to indicate the potential prognostic significance of the examined cytokines in NET patients undergoing PRRT, validation in larger and multi-center cohorts is needed to establish its clinical utility.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, V.V. and I.J.; experiments, N.G. and M.J. (Marina Jovanovic); formal analysis, M.J. (Milena Jurisevic); investigation, K.V.N., V.I. and J.D.; resources, S.J., B.P. and V.V.; data curation, K.V.N. and J.D.; writing&#8212;original draft, review and editing, K.V.N., N.G., I.J. and V.V.; visualization, M.J. (Milena Jurisevic); supervision, I.J.; project administration, V.V. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Clinical Center Kragujevac (number 01/22-385, approved on 4 November 2022).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data and materials supporting this study will not be publicly available due to ethical restrictions. The data will be available upon reasonable request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of this study, in the collection, analyses, or interpretation of data, in the writing of this manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-ijms-26-08526"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name></person-group><article-title>Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States</article-title><source>JAMA Oncol.</source><year>2017</year><volume>3</volume><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0589</pub-id><pub-id pub-id-type="pmid">28448665</pub-id><pub-id pub-id-type="pmcid">PMC5824320</pub-id></element-citation></ref><ref id="B2-ijms-26-08526"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benevento</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liccardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cannavale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Minotta</surname><given-names>R.</given-names></name><name name-style="western"><surname>DI Iasi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Colao</surname><given-names>A.</given-names></name></person-group><article-title>Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms</article-title><source>Minerva Endocrinol.</source><year>2024</year><volume>49</volume><fpage>158</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.23736/S2724-6507.23.04140-4</pub-id><pub-id pub-id-type="pmid">38625065</pub-id></element-citation></ref><ref id="B3-ijms-26-08526"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strosberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>El-Haddad</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wolin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hendifar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chasen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mittra</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kulke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacene</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>376</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607427</pub-id><pub-id pub-id-type="pmid">28076709</pub-id><pub-id pub-id-type="pmcid">PMC5895095</pub-id></element-citation></ref><ref id="B4-ijms-26-08526"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Santo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Virgolini</surname><given-names>I.</given-names></name></person-group><article-title>Peptide receptor radionuclide therapy of neuroendocrine tumors: Agonist, antagonist and alternatives</article-title><source>Semin. Nucl. Med.</source><year>2024</year><volume>54</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2024.02.002</pub-id><pub-id pub-id-type="pmid">38490913</pub-id></element-citation></ref><ref id="B5-ijms-26-08526"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puliani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chiefari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mormando</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bianchini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lauretta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Appetecchia</surname><given-names>M.</given-names></name></person-group><article-title>New insights in PRRT: Lessons from 2021</article-title><source>Front. Endocrinol.</source><year>2022</year><volume>13</volume><elocation-id>861434</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.861434</pub-id><pub-id pub-id-type="pmcid">PMC9016202</pub-id><pub-id pub-id-type="pmid">35450421</pub-id></element-citation></ref><ref id="B6-ijms-26-08526"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colotta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garlanda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name></person-group><article-title>Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability</article-title><source>Carcinogenesis</source><year>2009</year><volume>30</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp127</pub-id><pub-id pub-id-type="pmid">19468060</pub-id></element-citation></ref><ref id="B7-ijms-26-08526"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohlendorf</surname><given-names>F.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Henkenberens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bengel</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Derlin</surname><given-names>T.</given-names></name></person-group><article-title>Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>504</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11030504</pub-id><pub-id pub-id-type="pmid">33809226</pub-id><pub-id pub-id-type="pmcid">PMC8000284</pub-id></element-citation></ref><ref id="B8-ijms-26-08526"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou-Jokh Casas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Lago</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mall&#243;n Araujo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cabezas Agr&#237;cola</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nogareda Seoane</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cousillas Casti&#241;eira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruibal Morell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pubul N&#250;&#241;ez</surname><given-names>V.</given-names></name></person-group><article-title>Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis</article-title><source>Rev. Esp. Med. Nucl. Imagen Mol. (Engl. Ed.)</source><year>2023</year><volume>42</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.remnie.2023.02.006</pub-id><pub-id pub-id-type="pmid">37147033</pub-id></element-citation></ref><ref id="B9-ijms-26-08526"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satapathy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khosla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>B.R.</given-names></name></person-group><article-title>Hematological markers as predictors of treatment outcomes with Lutetium 177 (177Lu)-DOTATATE in patients with advanced neuroendocrine tumors</article-title><source>Cancer Biother. Radiopharm.</source><year>2022</year><volume>37</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1089/cbr.2021.0053</pub-id><pub-id pub-id-type="pmid">34185573</pub-id></element-citation></ref><ref id="B10-ijms-26-08526"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fourni&#233;</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Poupot</surname><given-names>M.</given-names></name></person-group><article-title>The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>2506</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02506</pub-id><pub-id pub-id-type="pmid">30416507</pub-id><pub-id pub-id-type="pmcid">PMC6212549</pub-id></element-citation></ref><ref id="B11-ijms-26-08526"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kassis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ranglack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koeberle</surname><given-names>V.</given-names></name><name name-style="western"><surname>Piiper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kronenberger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zeuzem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waidmann</surname><given-names>O.</given-names></name><name name-style="western"><surname>Radeke</surname><given-names>H.H.</given-names></name></person-group><article-title>High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma</article-title><source>Transl. Oncol.</source><year>2013</year><volume>6</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1593/tlo.12418</pub-id><pub-id pub-id-type="pmid">23730411</pub-id><pub-id pub-id-type="pmcid">PMC3660800</pub-id></element-citation></ref><ref id="B12-ijms-26-08526"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Minaya</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Vaish</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>M.M.O.</given-names></name></person-group><article-title>The Role of IL-33/ST2 Pathway in Tumorigenesis</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>2676</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19092676</pub-id><pub-id pub-id-type="pmid">30205617</pub-id><pub-id pub-id-type="pmcid">PMC6164146</pub-id></element-citation></ref><ref id="B13-ijms-26-08526"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>3281</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13133281</pub-id><pub-id pub-id-type="pmid">34209038</pub-id><pub-id pub-id-type="pmcid">PMC8268428</pub-id></element-citation></ref><ref id="B14-ijms-26-08526"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwa&#347;niak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Czarnik-Kwa&#347;niak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maziarz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aebisher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zieli&#324;ska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karczma-rek-Borowska</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tabarkiewicz</surname><given-names>J.</given-names></name></person-group><article-title>Scientific reports concerning the impact of interleu-kin 4, interleukin 10 and transforming growth factor &#946; on cancer cells</article-title><source>Cent. Eur. J. Immunol.</source><year>2019</year><volume>44</volume><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.5114/ceji.2018.76273</pub-id><pub-id pub-id-type="pmid">31530989</pub-id><pub-id pub-id-type="pmcid">PMC6745546</pub-id></element-citation></ref><ref id="B15-ijms-26-08526"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vukomanovic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nedic</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Radojevic</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Dagovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milosavljevic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Markovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ignjatovic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Simic Vukomanovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Djukic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sreckovic</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience</article-title><source>Front. Endocrinol.</source><year>2024</year><volume>14</volume><elocation-id>1270421</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2023.1270421</pub-id><pub-id pub-id-type="pmcid">PMC10840135</pub-id><pub-id pub-id-type="pmid">38317712</pub-id></element-citation></ref><ref id="B16-ijms-26-08526"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theiler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dierickx</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Igaz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grozinsky-Glasberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bournaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Dorisio</surname><given-names>T.</given-names></name><name name-style="western"><surname>O&#8217;Dorisio</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>D.</given-names></name><name name-style="western"><surname>Christ</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>6290</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13246290</pub-id><pub-id pub-id-type="pmid">34944910</pub-id><pub-id pub-id-type="pmcid">PMC8699207</pub-id></element-citation></ref><ref id="B17-ijms-26-08526"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogl</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Dobrindt</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Buscherm&#246;hle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bures</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pratschke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amthauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wetz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jann</surname><given-names>H.</given-names></name></person-group><article-title>Influence of gender on therapy and outcome of neuroendocrine tumors of gastroenteropancreatic origin: A single-center analysis</article-title><source>Visc. Med.</source><year>2020</year><volume>36</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1159/000505500</pub-id><pub-id pub-id-type="pmid">32110653</pub-id><pub-id pub-id-type="pmcid">PMC7036565</pub-id></element-citation></ref><ref id="B18-ijms-26-08526"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swiha</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>D.E.K.</given-names></name><name name-style="western"><surname>Sistani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khatami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abazid</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mujoomdar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Romsa</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Laidley</surname><given-names>D.T.</given-names></name></person-group><article-title>Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2022</year><volume>148</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s00432-021-03672-w</pub-id><pub-id pub-id-type="pmid">34110489</pub-id><pub-id pub-id-type="pmcid">PMC8752529</pub-id></element-citation></ref><ref id="B19-ijms-26-08526"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ertan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kara</surname><given-names>B.</given-names></name><name name-style="western"><surname>Isik Disci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vatansev</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koksal</surname><given-names>Y.</given-names></name></person-group><article-title>The importance of systemic inflammatory response index, systemic immune-inflammation index, and hemoglobin-albumin-lymphocytes-platelets (HALP) score in children with cancer</article-title><source>Iran. J. Pediatr.</source><year>2021</year><volume>31</volume><fpage>e118121</fpage><pub-id pub-id-type="doi">10.5812/ijp.118121</pub-id></element-citation></ref><ref id="B20-ijms-26-08526"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benevento</surname><given-names>E.</given-names></name><name name-style="western"><surname>Altieri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Minotta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liccardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cannavale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Iasi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Colao</surname><given-names>A.</given-names></name></person-group><article-title>Role of Bone Metastases in Lung Neuroendocrine Neoplasms: Clinical Presentation, Treatment and Impact on Prognosis</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>8957</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25168957</pub-id><pub-id pub-id-type="pmid">39201642</pub-id><pub-id pub-id-type="pmcid">PMC11354689</pub-id></element-citation></ref><ref id="B21-ijms-26-08526"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottaiano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Facchini</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Iacovino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santorsola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Facchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Mauro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Toscano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montopoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Mauro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quagliariello</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Impact of vitamin D levels on progression-free survival and response to neoadjuvant chemotherapy in breast cancer patients: A systematic review and meta-analysis</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>4206</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16244206</pub-id><pub-id pub-id-type="pmid">39766105</pub-id><pub-id pub-id-type="pmcid">PMC11674590</pub-id></element-citation></ref><ref id="B22-ijms-26-08526"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sikaris</surname><given-names>K.A.</given-names></name></person-group><article-title>The de Ritis ratio: The test of time</article-title><source>Clin. Biochem. Rev.</source><year>2013</year><volume>34</volume><fpage>117</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">24353357</pub-id><pub-id pub-id-type="pmcid">PMC3866949</pub-id></element-citation></ref><ref id="B23-ijms-26-08526"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lofthus</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Granger</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Mahaffey</surname><given-names>K.W.</given-names></name></person-group><article-title>Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction</article-title><source>Coron. Artery Dis.</source><year>2012</year><volume>23</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1097/MCA.0b013e32834e4ef1</pub-id><pub-id pub-id-type="pmid">22113063</pub-id></element-citation></ref><ref id="B24-ijms-26-08526"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Cancer cell metabolism: Warburg and beyond</article-title><source>Cell</source><year>2008</year><volume>134</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.08.021</pub-id><pub-id pub-id-type="pmid">18775299</pub-id></element-citation></ref><ref id="B25-ijms-26-08526"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornburg</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Clem</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Telang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>J.</given-names></name></person-group><article-title>Targeting aspartate aminotransferase in breast cancer</article-title><source>Breast Cancer Res.</source><year>2008</year><volume>10</volume><fpage>R84</fpage><pub-id pub-id-type="doi">10.1186/bcr2154</pub-id><pub-id pub-id-type="pmid">18922152</pub-id><pub-id pub-id-type="pmcid">PMC2614520</pub-id></element-citation></ref><ref id="B26-ijms-26-08526"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name></person-group><article-title>Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis</article-title><source>Int. J. Biol. Markers</source><year>2023</year><volume>38</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1177/03936155231154662</pub-id><pub-id pub-id-type="pmid">36775971</pub-id></element-citation></ref><ref id="B27-ijms-26-08526"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janisch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Parizi</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Mostafaei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lysenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Enikeev</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Egawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shariat</surname><given-names>S.F.</given-names></name></person-group><article-title>Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: A systematic review and meta-analysis</article-title><source>Int. J. Clin. Oncol.</source><year>2020</year><volume>25</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s10147-019-01578-9</pub-id><pub-id pub-id-type="pmid">31768692</pub-id><pub-id pub-id-type="pmcid">PMC6989419</pub-id></element-citation></ref><ref id="B28-ijms-26-08526"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorbye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hjortland</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Vestermark</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Ladekarl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundl&#246;v</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janson</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Garresori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hofsli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study</article-title><source>Br. J. Cancer</source><year>2025</year><volume>133</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/s41416-025-03054-w</pub-id><pub-id pub-id-type="pmid">40382522</pub-id><pub-id pub-id-type="pmcid">PMC12322073</pub-id></element-citation></ref><ref id="B29-ijms-26-08526"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalligeros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diamantopoulos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Toumpanakis</surname><given-names>C.</given-names></name></person-group><article-title>Biomarkers in small intestine NETs and carcinoid heart disease: A comprehensive review</article-title><source>Biology</source><year>2021</year><volume>10</volume><elocation-id>950</elocation-id><pub-id pub-id-type="doi">10.3390/biology10100950</pub-id><pub-id pub-id-type="pmid">34681049</pub-id><pub-id pub-id-type="pmcid">PMC8533230</pub-id></element-citation></ref><ref id="B30-ijms-26-08526"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name></person-group><article-title>Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>4709</fpage><lpage>4721</lpage><pub-id pub-id-type="doi">10.1002/cam4.2327</pub-id><pub-id pub-id-type="pmid">31222971</pub-id><pub-id pub-id-type="pmcid">PMC6712467</pub-id></element-citation></ref><ref id="B31-ijms-26-08526"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>P.F.</given-names></name></person-group><article-title>The role of immune cells phenotype in neuroendocrine tumors development</article-title><source>Discov. Oncol.</source><year>2025</year><volume>16</volume><fpage>993</fpage><pub-id pub-id-type="doi">10.1007/s12672-025-02870-z</pub-id><pub-id pub-id-type="pmid">40461862</pub-id><pub-id pub-id-type="pmcid">PMC12133667</pub-id></element-citation></ref><ref id="B32-ijms-26-08526"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geisler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hellberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knorr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eschrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loosen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wree</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hammerich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>6191</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11206191</pub-id><pub-id pub-id-type="pmid">36294509</pub-id><pub-id pub-id-type="pmcid">PMC9604855</pub-id></element-citation></ref><ref id="B33-ijms-26-08526"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yagi-Nakanishi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wakisaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Murono</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshizaki</surname><given-names>T.</given-names></name></person-group><article-title>Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue</article-title><source>Auris Nasus Larynx</source><year>2014</year><volume>41</volume><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.anl.2014.08.007</pub-id><pub-id pub-id-type="pmid">25193287</pub-id></element-citation></ref><ref id="B34-ijms-26-08526"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cayrol</surname><given-names>C.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>J.P.</given-names></name></person-group><article-title>Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine</article-title><source>Cytokine</source><year>2022</year><volume>156</volume><fpage>155891</fpage><pub-id pub-id-type="doi">10.1016/j.cyto.2022.155891</pub-id><pub-id pub-id-type="pmid">35640416</pub-id></element-citation></ref><ref id="B35-ijms-26-08526"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milosavljevic</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Pejnovic</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Mitrovic</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Simovic Markovic</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lukic</surname><given-names>M.L.</given-names></name></person-group><article-title>Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>18106</fpage><lpage>18115</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7635</pub-id><pub-id pub-id-type="pmid">26919112</pub-id><pub-id pub-id-type="pmcid">PMC4951275</pub-id></element-citation></ref><ref id="B36-ijms-26-08526"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>G.</given-names></name><name name-style="western"><surname>Florholmen</surname><given-names>J.</given-names></name></person-group><article-title>Polarization of cytokine profile from Th1 into Th2 along colorectal adenoma-carcinoma sequence: Implications for the biotherapeutic target?</article-title><source>Inflamm. Allergy Drug Targets</source><year>2008</year><volume>7</volume><fpage>94</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2174/187152808785107589</pub-id><pub-id pub-id-type="pmid">18691138</pub-id></element-citation></ref><ref id="B37-ijms-26-08526"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramamoorthi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gallen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Czerniecki</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kodumudi</surname><given-names>K.</given-names></name></person-group><article-title>Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>669474</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.669474</pub-id><pub-id pub-id-type="pmid">34012451</pub-id><pub-id pub-id-type="pmcid">PMC8126720</pub-id></element-citation></ref><ref id="B38-ijms-26-08526"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.J.</given-names></name></person-group><article-title>Interleukin-33 in Malignancies: Friends or Foes?</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>3051</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.03051</pub-id><pub-id pub-id-type="pmid">30619376</pub-id><pub-id pub-id-type="pmcid">PMC6306406</pub-id></element-citation></ref><ref id="B39-ijms-26-08526"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ameri</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Moradi Tuchayi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaalberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>2646</fpage><lpage>2651</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815016116</pub-id><pub-id pub-id-type="pmid">30696763</pub-id><pub-id pub-id-type="pmcid">PMC6377481</pub-id></element-citation></ref><ref id="B40-ijms-26-08526"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alim</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Keane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Souza-Fonseca-Guimaraes</surname><given-names>F.</given-names></name></person-group><article-title>Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment</article-title><source>Curr. Opin. Immunol.</source><year>2024</year><volume>86</volume><fpage>102409</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2023.102409</pub-id><pub-id pub-id-type="pmid">38154421</pub-id></element-citation></ref><ref id="B41-ijms-26-08526"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovanovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Radosavljevic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mitrovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Juranic</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jonjic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lukic</surname><given-names>M.L.</given-names></name></person-group><article-title>ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma</article-title><source>Eur. J. Immunol.</source><year>2011</year><volume>41</volume><fpage>1902</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.1002/eji.201141417</pub-id><pub-id pub-id-type="pmid">21484786</pub-id><pub-id pub-id-type="pmcid">PMC3746127</pub-id></element-citation></ref><ref id="B42-ijms-26-08526"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovanovic</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Pejnovic</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Radosavljevic</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Pantic</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Milovanovic</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Lukic</surname><given-names>M.L.</given-names></name></person-group><article-title>Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells</article-title><source>Int. J. Cancer</source><year>2014</year><volume>134</volume><fpage>1669</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1002/ijc.28481</pub-id><pub-id pub-id-type="pmid">24105680</pub-id></element-citation></ref><ref id="B43-ijms-26-08526"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name></person-group><article-title>IL-33 signaling fuels outgrowth and metastasis of human lung cancer</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2016</year><volume>479</volume><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.09.081</pub-id><pub-id pub-id-type="pmid">27644880</pub-id></element-citation></ref><ref id="B44-ijms-26-08526"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N.</given-names></name></person-group><article-title>The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis</article-title><source>Cancer Immunol. Res.</source><year>2016</year><volume>4</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0313</pub-id><pub-id pub-id-type="pmid">26839309</pub-id></element-citation></ref><ref id="B45-ijms-26-08526"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De la Fuente</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Hermoso</surname><given-names>M.A.</given-names></name></person-group><article-title>The IL-33/ST2 axis: Role in health and disease</article-title><source>Cytokine Growth Factor Rev.</source><year>2015</year><volume>26</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.07.017</pub-id><pub-id pub-id-type="pmid">26271893</pub-id></element-citation></ref><ref id="B46-ijms-26-08526"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Takamaru</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ochiya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takenaga</surname><given-names>K.</given-names></name></person-group><article-title>Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13589</fpage><pub-id pub-id-type="doi">10.1038/ncomms13589</pub-id><pub-id pub-id-type="pmid">27882929</pub-id><pub-id pub-id-type="pmcid">PMC5123057</pub-id></element-citation></ref><ref id="B47-ijms-26-08526"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;berg</surname><given-names>K.</given-names></name></person-group><article-title>Management of functional neuroendocrine tumors of the pancreas</article-title><source>Gland Surg.</source><year>2018</year><volume>7</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.21037/gs.2017.10.08</pub-id><pub-id pub-id-type="pmid">29629316</pub-id><pub-id pub-id-type="pmcid">PMC5876681</pub-id></element-citation></ref><ref id="B48-ijms-26-08526"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huszno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kolosza</surname><given-names>Z.</given-names></name></person-group><article-title>Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients</article-title><source>Oncol. Lett.</source><year>2019</year><volume>18</volume><fpage>6275</fpage><lpage>6283</lpage><pub-id pub-id-type="pmid">31788105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2019.10966</pub-id><pub-id pub-id-type="pmcid">PMC6865674</pub-id></element-citation></ref><ref id="B49-ijms-26-08526"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Prognostic role of the C-reactive protein/albumin ratio in patients with gynecological cancers: A meta-analysis</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>737155</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.737155</pub-id><pub-id pub-id-type="pmid">34778051</pub-id><pub-id pub-id-type="pmcid">PMC8581351</pub-id></element-citation></ref><ref id="B50-ijms-26-08526"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukui-Kawaura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawahara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>R.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Namura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>I.</given-names></name></person-group><article-title>A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer</article-title><source>Oncotarget</source><year>2021</year><volume>12</volume><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27944</pub-id><pub-id pub-id-type="pmid">33953845</pub-id><pub-id pub-id-type="pmcid">PMC8092343</pub-id></element-citation></ref><ref id="B51-ijms-26-08526"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovanovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simovic Markovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gajovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jurisevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Djukic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lukic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zdravkovic</surname><given-names>N.</given-names></name></person-group><article-title>Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression</article-title><source>World J. Gastroenterol.</source><year>2019</year><volume>25</volume><fpage>6465</fpage><lpage>6482</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i43.6465</pub-id><pub-id pub-id-type="pmid">31798282</pub-id><pub-id pub-id-type="pmcid">PMC6881509</pub-id></element-citation></ref><ref id="B52-ijms-26-08526"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruhwedel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rogasch</surname><given-names>J.M.M.</given-names></name><name name-style="western"><surname>Steinhagen</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Bolduan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amthauer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schatka</surname><given-names>I.</given-names></name></person-group><article-title>To perform, or not to perform interim PET: Questioning the impact of midtherapy evaluation during PRRT in GEP-NET patients</article-title><source>Clin. Nucl. Med.</source><year>2025</year><volume>50</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/RLU.0000000000005479</pub-id><pub-id pub-id-type="pmid">39388313</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-08526-f001" orientation="portrait"><label>Figure 1</label><caption><p>Systemic values of cytokines and ratios of interest. Based on the therapeutic response, all patients were divided into two groups: responders and non-responders. (<bold>A</bold>) Serum IL-33 concentrations (pg/mL), (<bold>B</bold>) Serum IL-4 concentrations (pg/mL), (<bold>C</bold>) Serum sST2 concentrations (pg/mL), (<bold>D</bold>) Serum TNF-&#945; concentrations (pg/mL), (<bold>E</bold>) Ratio of TNF-&#945; to IL-33, (<bold>F</bold>) Ratio of TNF-&#945; to IL-4. Systemic levels of IL-33, IL-4, sST2, and TNF-&#945; were measured by ELISA. Statistical significance was tested by Mann&#8211;Whitney U test; * <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08526-g001.jpg"/></fig><table-wrap position="float" id="ijms-26-08526-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08526-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographics and clinical characteristics of NET patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Responders<break/>(n = 37)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Non-Responders<break/>(n = 14)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (y)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.4 &#177; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.9 &#177; 2.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.453 <sup>&#167;</sup></td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (51.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (71.4%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.255 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (48.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (28.6%)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Performance status (ECOG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (75.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (78.6%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.828 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (24.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (21.4%)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Location of primary tumor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GEP-NETs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (67.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (85.7%)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.366 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown primary NETs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (18.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (8.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (7.1%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (7.1%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ki-67 (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.3 &#177; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.8 &#177; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.076 <sup>&#165;</sup></td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Grade</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G1/TC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (10.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (7.1%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.405 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G2/AC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (67.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (85.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (21.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (7.1%)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Metastatic spread</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphonodal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (75.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (78.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (91.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (92.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osseous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (24.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (14.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.692 <sup>&#163;</sup></td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Previous treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (40.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (50.0%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.715 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapy/targeted molecular therapies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (27.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (21.4%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No previous treatment </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (32.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (28.6%)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Long-acting SSA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Octreotide LAR (30 mg every 4 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (16.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (21.4%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.762 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lanreotide (120 mg every 4 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (81.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (78.6%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (2.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Functionality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (40.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (42.9%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.00 <sup>&#163;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (59.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (57.1%)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: TC: typical carcinoid; AC: atypical carcinoid. Data represent the mean value &#177; SEM, frequency (percentage). * <italic toggle="yes">p</italic>-values indicate differences between responders and non-responders. <sup>&#165;</sup> Student&#8217;s <italic toggle="yes">t</italic>-test; <sup>&#163;</sup> Chi-squared test; <sup>&#167;</sup> Mann&#8211;Whitney U test. <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-08526-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08526-t002_Table 2</object-id><label>Table 2</label><caption><p>Laboratory parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Laboratory Parameter</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Before the 1st PRRT Cycle</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Before the 2nd PRRT Cycle</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Responders</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Responders</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value *</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Responders</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Responders</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WBC (white blood cell count) (10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.08 &#177; 0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.37 &#177; 0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.013</bold>&#160;<sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.04 &#177; 0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.83 &#177; 0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.04</bold>&#160;<sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Absolute Neutrophil Count (10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.45 &#177; 0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.43 &#177; 0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.037</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.89 &#177; 0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.04 &#177; 0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.039</bold>&#160;<sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Absolute lymphocyte count (10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95 &#177; 0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40 &#177; 0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.03</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51 &#177; 0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 &#177; 0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.03</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Absolute monocyte count (10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 &#177; 0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39 &#177; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.002</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56 &#177; 0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45 &#177; 0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.029</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBC (red blood cell count) (10<sup>12</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.47 &#177; 0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.39 &#177; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.479 <sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.32 &#177; 0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.25 &#177; 0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.792 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemoglobin (g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132.73 &#177; 2.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122.93 &#177; 4.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.065 <sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130.16 &#177; 2.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123.24 &#177; 4.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.213 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platelets (10<sup>9</sup>/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">270.73 &#177; 15.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">216.38 &#177; 22.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.021</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">257.73 &#177; 14.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">222.79 &#177; 45.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.014</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NLR </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.55 &#177; 0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.71 &#177; 0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.527 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.19 &#177; 0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.10 &#177; 0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.688 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLR </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">205.75 &#177; 32.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">174.80 &#177; 23.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.883 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">225.61 &#177; 35.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">221.86 &#177; 58.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.673 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIRI </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.45 &#177; 0.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 &#177; 0.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.021</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.76 &#177; 0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 &#177; 0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.049</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SII </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">925.55 &#177; 121.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">495.62 &#177; 77.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.026</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">821.69 &#177; 105.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">538.26 &#177; 78.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.049</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.80 &#177; 2.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.55 &#177; 2.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.499 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.31 &#177; 1.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.72 &#177; 1.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.728 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total protein (g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.24 &#177; 0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.00 &#177; 1.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.241 <sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.49 &#177; 1.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.00 &#177; 1.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.983 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albumin (g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.65 &#177; 0.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.36 &#177; 0.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.711 <sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.32 &#177; 0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.86 &#177; 1.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.574 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRP/Alb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30 &#177; 0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26 &#177; 0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.506 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14 &#177; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15 &#177; 0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.738 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HALP score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.91 &#177; 3.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.58 &#177; 4.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.00 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.25 &#177; 2.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.34 &#177; 4.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.916 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AST (U/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.49 &#177; 2.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.36 &#177; 4.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.597 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.54 &#177; 2.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.5 &#177; 8.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.039</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.84 &#177; 3.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.50 &#177; 7.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.380 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.81 &#177; 9.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.29 &#177; 12.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.792 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Ritis ratio (AST/ALT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.20 &#177; 0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.28 &#177; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.635 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 &#177; 0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22 &#177; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.975 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGT (U/L) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.43 &#177; 11.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.14 &#177; 18.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.160 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.03 &#177; 11.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136.43 &#177; 62.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.387 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALP (U/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.81 &#177; 8.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.07 &#177; 16.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.435 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.06 &#177; 7.59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">185.75 &#177; 38.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.029</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LDH (U/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">415.81 &#177; 33.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">385.29 &#177; 31.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.941 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">399.05 &#177; 24.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">398.00 &#177; 30.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.816 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urea (mmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.43 &#177; 0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.71 &#177; 0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.907 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.30 &#177; 0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.19 &#177; 0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Creatinine (&#181;mol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.81 &#177; 2.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.84 &#177; 7.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.398 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.05 &#177; 2.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.79 &#177; 7.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.650 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.38 &#177; 3.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.36 &#177; 6.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.102 <sup>&#165;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.89 &#177; 3.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.76 &#177; 8.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.250 <sup>&#165;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CgA (ng/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">803.82 &#177; 157.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1065.95 &#177; 593.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.399 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">379.80 &#177; 82.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1265.99 &#177; 562.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.036</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5HIAA (&#181;mol/24 h)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150.85 &#177; 49.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">197.47 &#177; 91.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.241 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.35 &#177; 21.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276.02 &#177; 106.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.03</bold>&#160;<sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSE (ng/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.26 &#177; 8.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.31 &#177; 7.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.908 <sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.08 &#177; 2.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.44 &#177; 16.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.250 <sup>&#167;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin D (nmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.27 &#177; 4.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.83 &#177; 5.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.037</bold>&#160;<sup>&#167;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.26 &#177; 5.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48.28 &#177; 5.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>0.029</bold>&#160;<sup>&#167;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Data represent the mean value &#177; SEM. * <italic toggle="yes">p</italic>-values indicate differences between responders and non-responders before the 1st PRRT and before the 2nd PRRT cycle. <sup>&#165;</sup> Student&#8217;s <italic toggle="yes">t</italic>-test; <sup>&#167;</sup> Mann&#8211;Whitney U test. Significant values are in bold. <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-08526-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08526-t003_Table 3</object-id><label>Table 3</label><caption><p>Correlation between systemic values of cytokines of interest and clinical and laboratory data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Spearman&#8217;s Rho</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value *</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>IL-33</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>IL-4</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.747</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">0.001</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Disease progression</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.293</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">0.037</italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Neutrophil Count %</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&#8722;0.287</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">0.041</italic>
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>sST2</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Absolute Neutrophil Count</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.319</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">0.022</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Triglycerides</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#8722;0.277</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">0.049</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Lipase</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>&#8722;0.439</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">0.001</italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Gamma-glutamyl transferase</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.300</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">0.033</italic>
</td></tr></tbody></table><table-wrap-foot><fn><p>Significant values of Spearman&#8217;s rank correlation coefficients are in bold and italics. * <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-26-08526-t004" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08526-t004_Table 4</object-id><label>Table 4</label><caption><p>Factors associated with disease progression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Univariable<break/>OR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OR (95%CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value * </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (&gt;65)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.522</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0.4&#8211;5.791)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.538</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex (male)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.368</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.628&#8211;8.926</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.203</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Location of<break/>primary tumor (non-GEP-NETs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.880</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.554&#8211;14.960</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.208</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ki67(&gt;10%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.255</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.159&#8211;15.625</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CgA (&gt;600 ng/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.760</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.413&#8211;7.506</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.445</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSE (&gt;15 ng/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.297&#8211;4.424</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.844</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Il/33 (&gt;147 pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.552</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.159&#8211;15.628</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL4 (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;1.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.145</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sST2 (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;1.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.126</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNF (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.994&#8211;1.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.621</td></tr></tbody></table><table-wrap-foot><fn><p>Univariate binary logistic regression was performed, and significant values are shown in bold. * <italic toggle="yes">p</italic>-value &lt; 0.05 was considered statistically significant.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>